Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAX-CI in Metastatic Pancreatic Cancer
NCT03535727Phase 2
Key facts
- Status
- Completed
- Start
- Jun 2018
- Primary completion
- Oct 2022
- Countries
- 1
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Modality
- Small Molecules
- Drugs
- paclitaxel
- Conditions
- pancreatic adenocarcinoma (PDAC)
01
Overview
Phase 2, open-label trial of paclitaxel in pancreatic adenocarcinoma (PDAC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Jun 2018; status: completed.
02
Design
- Study design
- Non-randomizedOpen-label
03
Registry description
The purpose of this study is to evaluate the clinical activity of gemcitabine, nab-paclitaxel, capecitabine, cisplatin, and irinotecan (GAX-CI) in patients with metastatic pancreatic cancer.
Beyond the preview
Go deeper on NCT03535727.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03535727.